Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term growth-factor receptor. Found 33 abstracts

no pagination
Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Hague S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m(2) for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1391-8.   PMCID: no NIH
Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current treatment options in oncology. 2012 Sep;13(3):390-402.   PMCID: Not NIH funded
Zhou Y, Goenaga AL, Harms BD, Zou H, Lou JL, Conrad F, Adams GP, Schoeberl B, Nielsen UB, Marks JD. Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies. Molecular Cancer Therapeutics. 2012 Jul;11(7):1467-76.
Carlson RW, Allred C, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2011 Feb;9(2):136-222.   PMCID: not NIH funded - practice guideline
Huson SM, Acosta MT, Belzberg AJ, Bernards A, Chernoff J, Cichowski K, Evans DG, Ferner RE, Giovannini M, Korf BR, Listernick R, North KN, Packer RJ, Parada LF, Peltonen J, Ramesh V, Reilly KM, Risner JW, Schorry EK, Upadhyaya M, Viskochil DH, Zhu YA, Hunter-Schaedle K, Giancotti FG. Back to the Future: Proceedings From the 2010 NF Conference. American Journal of Medical Genetics Part A. 2011 Feb;155A(2):307-21.   PMCID: PMC3079924
Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus. Cancer. 2011 Apr;117(7):1409-14.   PMCID: PMC3116987
Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology. 2011 Jul;29(19):2660-6.   PMCID: not NIH funded
Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song LX, Rawal B, Schell MJ, Bepler G. Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2010 Mar;28(8):1387-94.   PMCID: PMC3040065
Motzer RJ, Hudes GR, Ginsberg MS, Baum MS, Harmon CS, Kim ST, Chen I, Redman BG. Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology-Cancer Clinical Trials. 2010 Dec;33(6):614-8.   PMCID: not NIH funded
Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman RA, Nakagawa M, Wu LZ, Klein-Szanto AJ, Herlyn M, Diehl JA, Katz JP, Pear WS, Seykora JT, Nakagawa H. NOTCH1 and NOTCH3 Coordinate Esophageal Squamous Differentiation Through a CSL-Dependent Transcriptional Network. Gastroenterology. 2010 Dec;139(6):2113-23.   PMCID: PMC2997138
Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno N, Cristofanilli M. Inflammatory Breast Cancer The Disease, the Biology, the Treatment. Ca-a Cancer Journal for Clinicians. 2010 Nov;60(6):351-75.   PMCID: not NIH funded
Sosa MS, Lopez-Haber C, Yang CF, Wang HB, Lemmon MA, Busillo JM, Luo JS, Benovic JL, Klein-Szanto A, Yagi H, Gutkind JS, Parsons RE, Kazanietz MG. Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer. Molecular cell. 2010 Dec;40(6):877-92.   PMCID: PMC3038344
Chen JQ, Russo J. ER alpha-negative and triple negative breast cancer: Molecular features and potential therapeutic approaches. Biochimica Et Biophysica Acta-Reviews on Cancer. 2009 Dec;1796(2):162-75.   PMCID: PMC2937358
de Camargo VP, van de Rijn M, de Alava E, Madoz-Gurpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Thomas DM. Other Targetable Sarcomas. Seminars in Oncology. 2009 Aug;36(4):358-71.   PMCID: not NIH funded
Engstrom PF, Arnoletti JP, Benson AB, Chen YJ, Choti MA, Cooper HS, Covey A, Dilawari RA, Early DS, Enzinger PC, Fakih MG, Fleshman J, Fuchs C, Grem JL, Kiel K, Knol JA, Leong LA, Lin E, Mulcahy MF, Rao S, Ryan DP, Saltz L, Shibata D, Skibber JM, Sofocleous C, Thomas J, Venook AP, Willett C. Colon Cancer. Journal of the National Comprehensive Cancer Network. 2009 Sep;7(8):778-831.   PMCID: no NIH - Practice Guideline
O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. CLINICAL CANCER RESEARCH. 2006 Jan;12(7):2255-63.
Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnology. 2005 Sep;23(9):1147-57.
Bartholomew PJ, Jones CW, Benware A, Chernoff J, LaFlamme SE. Regulation of the catalytic activity of PTP1B: Roles for cell adhesion, tyrosine residue 66, and proline residues 309 and 310. Experimental Cell Research. 2005 Dec 10;311(2):294-306.
Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study. Journal of Clinical Oncology. 2005 Dec;23(34):8646-54.
Cohen SJ, Cohen RB, Meropol NJ. Targeting signal transduction pathways in colorectal cancer - More than skin deep. Journal of Clinical Oncology. 2005 Aug 10;23(23):5374-85.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term growth-factor receptor

growth-factor receptor expression chemotherapy monoclonal-antibody gefitinib tyrosine kinase inhibitor carcinoma sensitivity survival phase-iii trial squamous-cell carcinoma family kinases tumors gastroesophageal junction lung-cancer combination endocrine therapy phase-ii irinotecan mutations gene-expression epithelial-cells multicenter NCCN Clinical Practice Guidelines metastatic colorectal-cancer positron-emission-tomography phase-ii trial neoplasm recurrence dna adduct formation modeling analysis in-vivo botulinum neurotoxin junction colonic neoplasms adjuvant chemotherapy neurofibromatosis type-2 renal cell carcinoma tumor spheroids long-term survival controlled-trial antitumor-activity placebo-controlled trial fluorouracil plus leucovorin soft part lymph-node micrometastases tumorigenesis randomized-trial signal-transduction amino-acid motifs neoadjuvant chemotherapy cancer plus cetuximab dose-escalation colorectal-cancer peripheral-nerve ibritumomab tiuxetan radioimmunotherapy preoperative chemoradiation surgical adjuvant insulin-receptor cell-cycle arrest apoptosis-inducing ligand human-melanoma cells biweekly cetuximab squamous cancer esophageal cancer-erlotinib-response evaluation esophagogastric 5-fluorouracil concurrent chemoradiotherapy NCCN Guidelines Oncology adenocarcinoma chronic lymphocytic-leukemia neutrophil function progesterone-receptor factor-kappa-b epidemiology oxaliplatin-based metastatic vasculogenic mimicry estrogen-receptor skin vegf high-dose microRNAs EGFR-Therapeutic approaches for TN-breast cancer-Triple negative breast cancer surgery advanced colorectal-carcinoma up-regulation gastrointestinal stromal tumors site barrier cyclin d1 rhoc gtpase glioblastoma spred1 estrogen-receptor-beta induced cell motility identification enhanced antitumor-activity serum-cholesterol giant-cell tumor Multimodality therapy Esophageal carcinoma-Neoadjuvant therapy-Chemotherapy-Radiotherapy-Gastroesophageal junction (GEJ)-Esophageal cancer-Treatment inhibitor colon-cancer quality-of-life sentinel-node biopsy sunitinib CXC chemokine Breast cancer-CXCL8-ER alpha-ER beta-Estrogen carcinogenesis-GRCP-30 carcinomas epithelium c225 b-cell lymphoma breast cancer body-mass index lymph-node metastases erlotinib beta-1-integrin conformation oxaliplatin schwannomatosis neurofibromatosis-NF1-NF2-neurofibroma-learning disabilities-bone dysplasia-MPNST in-vitro therapy cell-proliferation adenocarcinoma cells lobular carcinoma in situ postmenopausal women humanized anti-cd22 antibody peptides skin-sparing mastectomy PTP1B tyrosine phosphatase-cell adhesion-integrin epithelial-mesenchymal transition factor-related chronic myeloid-leukemia c-src cooperative-oncology-group sorafenib adjuvant therapy endoplasmic-reticulum ret protooncogene mutations colorectal tamoxifen resistance met neoadjuvant chemoradiation activated protein-kinase unresectable liver metastases bevacizumab spectrometry-based proteomics resistant mcf-7 cells dermatofibrosarcoma protuberans phenotype breast comparative genomic hybridization advanced solid tumors randomized
Last updated on Wednesday, July 08, 2020